A recent phase I clinical trial tested one such lipid, BP1001, an ASO that includes anti-growth factor receptor-bound protein 2 (Grb2) oligonucleotides with P-ethoxy backbone loaded on dioleoylphosphatidylcholine (DOPC), an ionizable cationic lipid, in individuals with acute myeloid leukemia, Philadelphia-chromosome-positive chronic myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The gene discussed is GRB2; the disease is acute myeloid leukemia.